文献速递心力衰竭与心肌病冠心病血脂与心血管预防

利格列汀对CARMELINA研究中高心血管和肾脏风险的2型糖尿病患者心力衰竭及相关结局的影响

Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.
PubMed 文献 · Circulation · 2019-01-01

CARMELINA试验的事后分析纳入6979例2型糖尿病合并动脉粥样硬化性心血管病和/或肾脏疾病患者,随机接受利格列汀5mg每日一次或安慰剂。中位随访2.2年,利格列汀未影响心力衰竭住院风险(HR 0.90,95%CI 0.74-1.08)、心血管死亡/心衰住院复合终点(HR 0.94,95%CI 0.82-1.08)或复发性心衰住院 events(率比0.94,95%CI 0.75-1.20)。

要点

  • 利格列汀不增加心衰住院风险,HR 0.90(95%CI 0.74-1.08)
  • 心血管死亡/心衰住院复合终点无显著差异,HR 0.94(95%CI 0.82-1.08)
  • 基线心衰病史、肾功能或左室射血分数不影响利格列汀对心衰的作用

核心结论

  • 在2型糖尿病合并动脉粥样硬化性心血管病和/或肾脏疾病患者中,利格列汀未影响心衰住院风险或其他选定的心衰相关结局。

研究设计与样本

  • CARMELINA是一项国际多中心随机对照试验,纳入27个国家6979例2型糖尿病合并动脉粥样硬化性心血管病和/或肾脏疾病患者,1:1随机接受利格列汀5mg每日一次或安慰剂。
  • 中位随访2.2年,平均年龄65.9岁,男性62.9%,糖尿病病程14.8年,基线心衰病史者1873例(26.8%)。

主要发现

  • 利格列汀组心衰住院发生率为6.0%(209/3494),安慰剂组为6.5%(226/3485),HR 0.90(95%CI 0.74-1.08)。
  • 心血管死亡/心衰住院复合终点HR 0.94(95%CI 0.82-1.08)。
  • 复发性心衰住院 events:利格列汀组326次 vs 安慰剂组359次,率比0.94(95%CI 0.75-1.20)。
  • 基线心衰病史、基线eGFR或尿白蛋白肌酐比、随机前左室射血分数均未显示利格列汀对心衰住院效应的异质性。

关键数值与推荐

  • 利格列汀5mg每日一次口服,在标准治疗基础上加用。
  • 心衰住院HR 0.90(95%CI 0.74-1.08),心血管死亡/心衰住院HR 0.94(95%CI 0.82-1.08),复发性心衰住院率比0.94(95%CI 0.75-1.20)。

临床怎么用

  • 对于2型糖尿病合并动脉粥样硬化性心血管病和/或肾脏疾病患者,使用利格列汀不增加心衰住院风险。
  • 无论基线是否有心衰病史、肾功能状态或左室射血分数如何,利格列汀对心衰的影响一致。

局限性

  • 本分析为CARMELINA试验的二次分析,心衰相关结局并非主要终点。
  • 左室射血分数仅在部分参与者中于随机前一年内获取,亚组分析受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Individuals with type 2 diabetes mellitus are at increased risk for heart failure (HF), particularly those with coexisting atherosclerotic cardiovascular disease and/or kidney disease. Some but not all dipeptidyl peptidase-4 inhibitors have been associated with increased HF risk. We performed secondary analyses of HF and related outcomes with the dipeptidyl peptidase-4 inhibitor linagliptin versus placebo in CARMELINA (The Cardiovascular and Renal Microvascular Outcome Study With Linagliptin), a cardiovascular outcomes trial that enrolled participants with type 2 diabetes mellitus and atherosclerotic cardiovascular disease and/or kidney disease. METHODS: Participants in 27 countries with type 2 diabetes mellitus and concomitant atherosclerotic cardiovascular disease and/or kidney disease were randomized 1:1 to receive once daily oral linagliptin 5 mg or placebo, on top of standard of care. All hospitalization for HF (hHF), cardiovascular outcomes, and deaths were prospectively captured and centrally adjudicated. In prespecified and post hoc analyses of HF and related events, Cox proportional hazards models adjusting for region and baseline history of HF were used. Recurrent hHF events were analyzed using a negative binomial model. In a subset of participants with left ventricular ejection fraction captured within the year before randomization, HF-related outcomes were assessed in subgroups stratified by left ventricular ejection fraction > or ≤50%. RESULTS: CARMELINA enrolled 6979 participants (mean age, 65.9 years; estimated glomerular filtration rate, mL/min per 1.73m2; hemoglobin A1c, 8.0%; 62.9% men; diabetes mellitus duration, 14.8 years), including 1873 (26.8%) with a history of HF at baseline. Median follow-up was 2.2 years. Linagliptin versus placebo did not affect the incidence of hHF (209/3494 [6.0%] versus 226/3485 [6.5%], respectively; hazard ratio [HR], 0.90; 95% CI, 0.74-1.08), the composite of cardiovascular death/hHF (HR, 0.94; 95% CI, 0.82-1.08), or risk for recurrent hHF events (326 versus 359 events, respectively; rate ratio, 0.94; 95% CI, 0.75-1.20). There was no heterogeneity of linagliptin effects on hHF by history of HF at baseline, baseline estimated glomerular filtration rate or urine albumin-creatinine ratio, or prerandomization left ventricular ejection fraction. CONCLUSIONS: In a large, international cardiovascular outcome trial in participants with type 2 diabetes mellitus and concomitant atherosclerotic cardiovascular disease and/or kidney disease, linagliptin did not affect the risk of hHF or other selected HF-related outcomes, including among participants with and without a history of HF, across the spectrum of kidney disease, and independent of previous left ventricular ejection fraction. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01897532.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. McGuire DK, Alexander JH, Johansen OE, et al. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. Circulation. 2019. PMID: 30586723. doi:10.1161/CIRCULATIONAHA.118.038352

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。